I’m not sure where to start. Yesterday I read a post on LinkedIn from someone who retired from our industry and is fighting MLS. She’s fighting with Medicare Advantage over treatment which will cost her $9,300 out-of-pocket. She asks, “why develop new treatments and make them only accessible to commercially insured patients?” She says, “as a past Pharma exec, we say a lot about putting the patient at the center of all we do and being patient-focused. But, I can tell you – sitting on the other side, being a patient with ALS – and constantly fighting for care – patients are not the most important priority. Sad to realize this.”